MPTP induces dystonia and parkinsonism: Clues to the pathophysiology of dystonia

Neurology

Volumn 49, Issue 5, 1997, Pages 1432-1438

  Perlmutter, Joel S ^a,b,c   Tempel, L W ^a,b   Black, K J ^a,b   Parkinson, D ^a   Todd, R D ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE;

ANIMAL MODEL; ARTICLE; BABOON; BRADYKINESIA; DOPAMINERGIC SYSTEM; DYSTONIA; MALE; MOTOR DYSFUNCTION; NEUROTOXICITY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSONISM; PATHOPHYSIOLOGY; PRIORITY JOURNAL; TREMOR;

EID: 0030659028     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.49.5.1432     Document Type: Article

References (46)

1. Hornykiewicz O. Die topische lokalisation und das verhalten von noradrenalin und dopamin in der substantia nigra des normalen und Parkinsonkranken Menschen. Wien Klin Wochenschr 1963;75:309-312.
2. Wooten GF, Trugman JM. The dopamine motor system Mov Disord 1989;4:S38-S47.
3. Burns RS, Chiueh CC, Markey SP, Ebert MH, Jacobowitz DM, Kopin IJ. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methy]-1-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci USA 1983;80:4546-4550.
4. Ballard PA, Tetrud JW, Langsten JW. Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases. Neurology 1985;35:949-956.
5. Jenner P, Marsden CD. MPTP-induced parkinsonism: a model of Parkinson's disease and its relevance to the disease process. In: Jankovic J, Tolosa, eds. Parkinson's disease and movement disorders. 2nd ed. Baltimore: Williams & Wilkins, 1993:55-76.
6. Fahn S. Concept and classification of dystonia. Adv Neurol 1988;50:1-8.
7. Bressman S, Heiman G, Nygaard T, et al. A study of idiopathic torsion dystonia in a non-Jewish family: evidence for genetic heterogeneity. Neurology 1994;44:283-287.
8. Bhatia K, Marsden CD. The behavioural and motor consequences of focal lesions of the basal ganglia in man. Brain 1994;117:859-876.
9. Garver D, Davis J, Dekirmenjian H, et al. Dystonic reactions following neuroleptics: time course and proposed mechanisms. Psychopharmacology (Berl) 1976;47:199-201.
10. Kolbe H, Clow A, Jenner P, Marsden CD. Neuroleptic-induced acute dystonic reactions may be due to enhanced dopamine release on to supersensitive postsynaptic receptors. Neurology 1981;31:434-439.
11. Rupniak N, Jenner P, Marsden CD. Acute dystonia induced by neuroleptic drugs. Psychopharmacology (Berl) 1986;88: 403-419.
12. Nygaard TG, Marsden CD, Fahn S. Dopa-responsive dystonia: long-term treatment response and prognosis. Neurology 1992; 41:174-181.
13. Harwood G, Hierons R, Fletcher N, Marsden CD. Lessons from a remarkable family with dopa-responsive dystonia. J Neurol Neurosurg Psychiatry 1994;57:460-463.
14. Knappskog PM, Flatmark T, Mallet J, Ludecke B, Bartholome K. Recessively inherited L-dopa-responsive dystonia caused by a point mutation (Q381K) in the tyrosine hydroxylase gene. Hum Mol Genet 1995;4:1209-1212.
15. Mitchell I, Luguin R, Boyce S, et al. Neural mechanisms of dystonia: evidence from a 2-deoxyglucose uptake study in a primate model of dopamine agonist-induced dystonia. Mov Disord 1990;5:49-54.
16. 3 receptor protein and mRNA in responses to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) denervation in baboons. J Neurosci 1996;16:7776-7782.
17. Parkinson D, Baughman R, Masland RH, Rando RR. Dopamine metabolism following irreversible inactivation of aromatic amino acid decarboxylase in retina. J Neurosci 1981;1: 1205-1210.
18. Bankiewicz K, Oldfield E, Chiueh C, Doppman J, Jacobowitz D, Kopin I. Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Life Sci 1986;39:7-16.
19. Guttman M, Fibiger HC, Jakubovic A, Calne DB. Intracarotid 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration: biochemical and behavioral observations in a primate model of hemiparkinsonism. J Neurochem 1990;54:1329-1334.
20. Palombo E, Porrino LJ, Bankiewicz KS, Crane AM, Sokoloff L, Kopin IJ. Local cerebral glucose utilization in monkeys with hemiparkinsonism induced by intracarotid infusion of the neurotoxin MPTP. J Neurosci 1990;10:860-869.
21. Joyce JN, Marshall JF, Bankiewicz KS, Kopin IJ, Jacobowitz DM. Hemiparkinsonism in a monkey after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is associated with regional ipsilateral changes in striatal dopamine D-2 receptor density Brain Res 1986;382:360-364.
22. 18F]dopa uptake in familial idiopathic dystonia Brain 1993;116:1191-1199.
23. Ashizawa T, Patten B, Jankovic J. Meige's syndrome. South Med J 1980;73:863-866.
24. Hornykiewicz O, Kish SJ, Becker LE, Farley I, Shannak K. Brain neurotransmitters in dystonia musculorum deformans N Engl J Med 1986;315:347-353.
25. Nygaard T. Dopa-responsive dystonia. Curr Opin Neurol 1995;8:310-313.
26. Lang AE. Hemiatrophy, juvenile-onset exertional alternating leg paresis, hypotonia, and hemidystonia and adult-onset hemiparkinsonism: the spectrum of hemiparkinsonism-hemiatrophy syndrome. Mov Disord 1995;10:489-495.
27. Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends Neurosci 1989;12:366-375.
28. Alexander GE, Crutcher MD. Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci 1990;13:266-271.
29. Gerfen CR, Engber TM, Mahan LC, et al. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 1990;250:1429-1432.
30. Gerfen CR. The neostriatal mosaic: multiple levels of compartmental organization. Trends Neurosci 1992;15:133-139.
31. Keefe KA, Gerfen CR. D1-D2 dopamine receptor synergy in striatum: effects of intrastriatal infusions of dopamine agonists and antagonists on immediate early gene expression. Neuroscience 1995;66:903-913.
32. 18F]spiperone binding in putamen in idiopathic focal dystonia. J Neurosci 1997;17:834-842.
33. Tempel L, Perlmutter J. Abnormal vibration-induced cerebral blood flow responses in dystonia. Brain 1990;113:691-707.
34. Tempel LW, Perlmutter JS. Abnormal cortical responses to vibration in patients with writer's cramp. Neurology 1993;43: 2252-2257.
35. Mink JW, Thach WT. Basal ganglia intrinsic circuits and their role in behavior. Curr Opin Neurobiol 1993;3:950-957.
36. Mink JW. The basal ganglia: focused selection and inhibition of competing motor programs. Prog Neurobiol 1996;50:381-425.
37. Gerfen CR, McGintry JF, Young WS. Dopamine differentially regulates dynorphin, substance P and enkephalin expression in striatal neurons: in situ hybridization histochemical analysis. J Neurosci 1991;11:1016-1031.
38. Black KJ, Gado MH, Perlmutter JS. PET measurement of dopamine D2 receptor-mediated changes in striatopallidal function. J Neurosci 1997;17:3168-3177.
39. Filion M, Tremblay L. Abnormal spontaneous activity of globus pallidus neurons in monkey with MPTP-induced parkinsonism. Brain Res 1991;547:142-151.
40. Perlmutter JS, Moerlein S, Huang D-R, Todd R. Non-steady-state measurement of in vivo radioligand binding with positron emission tomography: specificity analysis and comparison with in vitro binding. J Neurosci 1991;11:1381-1389.
41. Naumann M, Pirker W, Reiners K, Brücke T. Imaging the pre- and postsynaptic side of striatal dopaminergic synapses in idiopathic focal dystonia: a SPECT study using β-CIT and epidepride. Mov Disord 1990;11(suppl 1):206.
42. Sheehy M, Marsden C. Writer's cramp - a focal dystonia. Brain 1982;105:461-480.
43. Forno LS, Langston JW, DeLanney LE, Irwin I, Ricaurte GA. Locus coeruleus lesions and eosinophilic inclusions in MPTP-treated monkeys. Ann Neurol 1986;20:449-455.
44. Papa SM, Chase TN. Levodopa-induced dyskinesias improved by a glutamate antagonist in parkinsonian monkeys. Ann Neurol 1996;39:557-558.
45. Rupniak N, Boyce S, Steventon M, Iversen S, Marsden CD. Dystonia induced by combined treatment with L-dopa and MK-801 in parkinsonian monkeys. Ann Neurol 1992;32: 103-105.
46. Greenamyre JT, Eller RV, Zhang Z, et al. Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease. Ann Neurol 1994;35:655-661.